Heterogeneous nuclear ribonucleoprotein K pseudogene 3 (HNRNPKP3)

Heterogeneous nuclear ribonucleoprotein K pseudogene 3 (HNRNPKP3) is classified as a pseudogene in the human genome[1]. Pseudogenes like HNRNPKP3 are DNA sequences similar to known genes but typically lack the ability to encode functional proteins due to disruptive mutations or frameshifts[3]. The parental gene, HNRNPK, encodes an RNA/DNA-binding protein implicated in transcriptional regulation, RNA processing, and cell cycle control[2][4]; however, HNRNPKP3 does not produce protein and thus is generally not considered a direct therapeutic target[1].\n\nSome pseudogenes exhibit biological activity as competitive endogenous RNAs (ceRNAs), potentially influencing cellular pathways by regulating availability of microRNAs or RNA-binding proteins, which in turn may modulate gene expression[3][5]. There is evolving interest in the regulatory roles of pseudogenes in cancer biology and other diseases, but specific evidence or mechanisms for HNRNPKP3 have not been documented[1][3][5]. Consequently, it is not recognized as a validated drug target, diagnostic marker, or biomarker.\n\nHNRNPKP3 is not a protein, receptor, enzyme, or transporter, and there is no evidence indicating it serves as a direct therapeutic target. It is a non-coding pseudogene with potential transcript-level regulatory functions that remain to be fully characterized. The name is correct, but its relevance as a molecular target is limited, and it should not be included in structured therapeutic target panels without further evidence.

Other names

HNRNPKP3heterogeneous nuclear ribonucleoprotein K pseudogene 3

Not applicable; no known mechanisms of drug action for this pseudogene